1
|
Liang J, Ma R, Chen H, Zhang D, Ye W, Shi C, Luo L. Detection of Hyperacute Reactions of Desacetylvinblastine Monohydrazide in a Xenograft Model Using Intravoxel Incoherent Motion DWI and R2* Mapping. AJR Am J Roentgenol 2019; 212:717-726. [PMID: 30699010 DOI: 10.2214/ajr.18.20517] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
OBJECTIVE This study aimed to investigate the feasibility of intravoxel incoherent motion (IVIM) DWI and R2* (transverse relaxation rate) mapping to monitor the hyperacute therapeutic efficacy of desacetylvinblastine monohydrazide (DAVLBH) on an experimental hepatocellular carcinoma mouse model within 24 hours. MATERIALS AND METHODS Forty-four mice were implanted with hepatocellular carcinoma and divided into three random groups. A treatment group and a control group underwent IVIM-DWI and R2* mapping examinations before and after a single injection of DAVLBH or saline at 1, 2, 4, and 24 hours. The pathology group was set for pathologic analysis, including H and E staining and CD31 and hypoxia-inducible factor (HIF)-1α immunohistochemical staining. RESULTS DAVLBH caused hyperacute disruptions on the tumor capillaries in the treatment group. Water molecule diffusion (D), microcirculation perfusion (D*), and perfusion fraction (f) decreased initially but then gradually recovered to the baseline level by 24 hours after the first injection of DAVLBH. In contrast, R2* increased dramatically at 1 hour and then gradually decreased from 1 hour to 24 hours after treatment. D*, f, and D showed similar trends and were positively correlated with CD31 expression (r = 0.868, 0.721, and 0.730, respectively), but were negatively correlated with HIF-1α expression (r = -0.784, -0.737, and -0.673, respectively). R2* showed a negative correlation with CD31 expression (r = -0.823) and a positive correlation with HIF-1α expression (r = 0.791). CONCLUSION Both IVIM-DWI and R2* mapping can adequately detect the vascular-disrupting effect of DAVLBH as early as 1 hour after injection in a mouse xenograft model. Moreover, D* and R2* are the two most sensitive hemodynamic parameters and can monitor the hyperacute changes associated with DAVLBH treatment in vivo.
Collapse
Affiliation(s)
- Jianye Liang
- 1 Medical Imaging Center, The First Affiliated Hospital of Jinan University, No. 613, Huangpu Rd West, Tianhe District, Guangzhou, Guangdong 510630, China
| | - Rong Ma
- 2 Department of Radiology, The First Affiliated Hospital of Hunan Normal University, Changsha, China
| | - Heru Chen
- 3 College of Pharmacy, Jinan University, Guangzhou, China
| | - Dongmei Zhang
- 3 College of Pharmacy, Jinan University, Guangzhou, China
| | - Wencai Ye
- 3 College of Pharmacy, Jinan University, Guangzhou, China
| | - Changzheng Shi
- 1 Medical Imaging Center, The First Affiliated Hospital of Jinan University, No. 613, Huangpu Rd West, Tianhe District, Guangzhou, Guangdong 510630, China
| | - Liangping Luo
- 1 Medical Imaging Center, The First Affiliated Hospital of Jinan University, No. 613, Huangpu Rd West, Tianhe District, Guangzhou, Guangdong 510630, China
| |
Collapse
|
2
|
Dahlgren C, Norberg B, Eriksson S. The adherence of polymorphonuclear leucocytes to an albumin-coated glass surface. Effects of therapeutic concentrations of the Catharantus derivatives vincristine, vinblastine and vindesine. Acta Med Scand 2009; 221:109-13. [PMID: 3565080 DOI: 10.1111/j.0954-6820.1987.tb01251.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The Catharantus derivatives are microtubule antagonists employed in immunosuppression and chemotherapy of neoplasms. The role of cytoplasmic microtubules in polymorphonuclear leucocyte (PMN) adherence was studied by means of therapeutic concentrations of the Catharantus derivatives vincristine, vinblastine and vindesine. PMN adherence was measured as retention on an albumin-coated glass surface. PMN adherence was reduced by 4-54% by the Catharantus derivatives, as compared with control values. The suppression of adherence was statistically significant. Since the Catharantus derivatives are microtubule antagonists, it is reasonable to assume that PMN adherence is a partially microtubule-dependent process. It is suggested that reduction of PMN adherence could account for at least part of the immunosuppressive properties of the Catharantus derivatives.
Collapse
|
3
|
Paffhausen T, Schwab M, Westermann F. Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells. Cancer Lett 2007; 250:17-24. [PMID: 17141950 DOI: 10.1016/j.canlet.2006.09.010] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2006] [Accepted: 09/13/2006] [Indexed: 11/15/2022]
Abstract
Neuroblastoma (NB) is a solid childhood tumour that exhibits heterogeneous biological and clinical phenotypes. Multiple drug resistance marks a major complication especially in high-risk patients with advanced tumour stages and specific genetic aberrations, such as MYCN amplification and lp deletion. As an approach to further address the mechanisms of chemotherapeutic responsiveness of NB, we used a MYCN-inducible in vitro system and tested the susceptibility of NB cells to anti-tumour drugs currently included in NB treatment protocols dependent on MYCN expression. We observed cytotoxic effects using drug concentrations corresponding to blood plasma levels achieved in NB patients. The most potent drugs were microtubule inhibitors vindesin, paclitaxel and vincristin. Less effective were doxorubicine, arsenic trioxide, cisplatin, etoposide and carboplatin. Exposed to anti-tumour agents, NB cells with induced MYCN expression exhibited higher specific apoptosis than NB cells lacking MYCN expression. Anti-tumour drugs in MYCN-on cells accelerated G1-S phase transition, led to enhanced accumulation of cell populations in G2/M phase, and increased levels of apoptosis. In contrast, MYCN-off cell populations arrested in G1 and, to a smaller extent, in G2/M and exhibited delayed onset of apoptosis. In summary, apoptosis profiles and anti-proliferative potential of chemotherapeutic drugs, used at in vivo tolerable doses, are affected by MYCN overexpression and deregulated cell cycle in SH-EP(MYCN) cells.
Collapse
Affiliation(s)
- Tobias Paffhausen
- Division of Tumour Genetics, German Cancer Research Center, DKFZ, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany
| | | | | |
Collapse
|
4
|
Yoshida M, Matsui Y, Ikarashi Y, Usui T, Osada H, Wakasugi H. Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells. Anticancer Res 2007; 27:729-36. [PMID: 17465195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
Pironetin, isolated from Streptomyces sp., is a potent inhibitor of microtubule assembly and the first compound identified that covalently binds to alpha-tubulin at Lys352. We examined whether pironetin is an effective agent against human small cell lung cancer H69 cells, including two cell lines resistant to the microtubule-targeted drugs vindesine (H69/VDS) and paclitaxel (H69/Txl) that interact with beta-tubulin. Pironetin was found to be effective against these resistant cells as well as their parental cells. In addition, pironetin inhibited the growth of human leukemic K562 multidrug-resistant cells (K562/ADM), which have mdr1 gene expression, as well as the parental K562 cells. In these cell lines, including the parental and resistant cells, pironetin caused complete mitotic arrest; in addition, apoptosis inductions by 30 and 100 nM pironetin were observed. In this study, the new mitotic inhibitor, pironetin, was found to be effective not only against human tumor cell lines resistant to microtubule-targeted drugs, but also multidrug-resistant cells with mdr1 gene expression. These results suggest that pironetin is a useful agent for overcoming drug resistance in cancer chemotherapy.
Collapse
Affiliation(s)
- Mitsuzi Yoshida
- Pharmacology Division, National Cancer Center Research Institute, 5-1-1 Tsukiji Chuo-ku, Tokyo 104-0045, Japan.
| | | | | | | | | | | |
Collapse
|
5
|
Ma S, Egyházi S, Ueno T, Lindholm C, Kreklau EL, Stierner U, Ringborg U, Hansson J. O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma. Br J Cancer 2003; 89:1517-23. [PMID: 14562026 PMCID: PMC2394337 DOI: 10.1038/sj.bjc.6601270] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
In a retrospective study, O6-methylguanine-DNA-methyltransferase (MGMT) expression was analysed by immunohistochemistry using monoclonal human anti-MGMT antibody in melanoma metastases in patients receiving dacarbazine (DTIC) as single-drug therapy or as part of combination chemotherapy with DTIC–vindesine or DTIC–vindesine–cisplatin. The correlation of MGMT expression levels with clinical response to chemotherapy was investigated in 79 patients with metastatic melanoma. There was an inverse relationship between MGMT expression and clinical response to DTIC-based chemotherapy (P=0.05). Polymorphisms in the coding region of the MGMT gene were also investigated in tumours from 52 melanoma patients by PCR/SSCP and nucleotide sequence analyses. Single-nucleotide polymorphisms (SNPs) in exon 3 (L53L and L84F) and in exon 5 (I143V/K178R) were identified. There were no differences in the frequencies of these polymorphisms between these melanoma patients and patients with familial melanoma or healthy Swedish individuals. Functional analysis of variants MGMT-I143V and -I143V/K178R was performed by in vitro mutagenesis in Escherichia coli. There was no evidence that these variants decreased the MGMT DNA repair activity compared to the wild-type protein. All melanoma patients with the MGMT 53/84 polymorphism except one had tumours with high MGMT expression. There was no significant correlation between any of the MGMT polymorphisms and clinical response to chemotherapy, although an indication of a lower response rate in patients with SNPs in exon 5 was obtained. Thus, MGMT expression appears to be more related to response to chemotherapy than MGMT polymorphisms in patients with metastatic melanoma.
Collapse
Affiliation(s)
- S Ma
- Department of Oncology/Pathology, Cancer Centre Karolinska, Karolinska Hospital, S-171 76 Stockholm, Sweden
| | - S Egyházi
- Department of Oncology/Pathology, Cancer Centre Karolinska, Karolinska Hospital, S-171 76 Stockholm, Sweden
| | - T Ueno
- Department of Oncology/Pathology, Cancer Centre Karolinska, Karolinska Hospital, S-171 76 Stockholm, Sweden
| | - C Lindholm
- Department of Oncology, Ryhov County Hospital, Jönköping, Sweden
| | - E L Kreklau
- Indiana University Cancer Centre, Department of Pharmacology/Toxicology, Indiana University School of Medicine, Indianapolis, IN, USA
| | - U Stierner
- Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - U Ringborg
- Department of Oncology/Pathology, Cancer Centre Karolinska, Karolinska Hospital, S-171 76 Stockholm, Sweden
| | - J Hansson
- Department of Oncology/Pathology, Cancer Centre Karolinska, Karolinska Hospital, S-171 76 Stockholm, Sweden
- Department of Oncology/Pathology, Cancer Centre Karolinska, Karolinska Hospital, S-171 76 Stockholm, Sweden. E-mail:
| |
Collapse
|
6
|
Merighi S, Mirandola P, Varani K, Gessi S, Capitani S, Leung E, Baraldi PG, Tabrizi MA, Borea PA. Pyrazolotriazolopyrimidine derivatives sensitize melanoma cells to the chemotherapic drugs: taxol and vindesine. Biochem Pharmacol 2003; 66:739-48. [PMID: 12948854 DOI: 10.1016/s0006-2952(03)00400-3] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
In this study, we have evaluated the "in vitro" modulatory activity of a series of pyrazolotriazolopyrimidine derivatives (PTP-d) in sensitizing malignant melanoma cells to the chemotherapic drugs: taxol and vindesine. To that end, we have described the impact of chemotherapeutic agents on the cell cycle and on the induction of apoptosis when used alone or in combination with PTP-d. We have demonstrated that four PTP-d reduced chemotherapic drugs EC(50) doses of the G(2)/M accumulation with an average of 1.7-fold for taxol and 9.5-fold for vindesine when challenged on A375 human melanoma cell line. This sensitization activity was also confirmed by analyzing the apoptosis degree induced by the chemotherapic drugs. Interestingly, PTP-d had no effects on the response to cytotoxic agents by skin-derived human keratinocyte cells, NCTC 2544. Therefore, we have investigated the signaling pathway sustaining the sensitizing effect of PTP-d, providing functional evidence that active compounds are able to inhibit multidrug resistance-associated ATP-binding cassette drug transporter. These results suggested that PTP-d hold great promise for the treatment of multidrug resistance in cancers, leading to potential new therapies for melanoma.
Collapse
Affiliation(s)
- Stefania Merighi
- Department of Clinical and Experimental Medicine, Pharmacology Unit, University of Ferrara, 44100 Ferrara, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Chen W, Zhou X, Xu Q, Guo W, Lin L. [Chemosensitivity testing of oral and maxillofacial cancer with biopsy specimens]. Zhonghua Kou Qiang Yi Xue Za Zhi 2002; 37:404-7. [PMID: 12641948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
Abstract
OBJECTIVE To determine the chemosensitivity in fresh biopsy specimen of human oral and maxillofacial cancer, and the differential chemosensitivity among those drugs used popularly in clinic. METHODS Human biopsy cancer cells were obtained from 150 oral and maxillofacial malignant tumors. The antitumor drugs tested using modified MTT assay were cisplatin (CDDP), 5-fluorouracil (5-Fu), Pinyangmycin (PYM), Paclitaxel (Taxol), Teniposide (Vm-26), Epi-adriamycin (E-ADM), Vindesin (VDS) and Methortrexatum (MTX). RESULTS The success rate of the MTT assay was 93.33% (140 of the 150 cases). At a drug concentration of Cmax x 5, the inhibition rates of oral tumor cells were 63.76% for Vm-26, 25.93% for CDDP, 25.86% for E-ADM, 23.52% for Taxol, 22.97% for PYM, 22.08% for 5-Fu, 18.42% for VDS and 18.93% for MTX. The inhibition rate of VM26 was significantly higher than any of other seven chemotherapeutic drugs (P < 0.05). Over forty percent patients with squamous cell carcinoma showed moderate chemosensitivity to VM-26, CDDP and E-ADM, and over forty percent cases with adenoid carcinoma showed moderate chemosensitivity to Vm-26, Taxol and E-ADM. CONCLUSIONS Most oral and maxillofacial cancers showed chemosensitivity to Vm-26, CDDP, E-ADM and Taxol. Vm-26, E-ADM and Taxol were more potent drugs than VDS, 5-Fu and MTX against oral and maxillofacial cancer cells. Chemosensitivity testing using modified MTT assay was useful in selecting antitumor drugs for patients with oral and maxillofacial cancers.
Collapse
Affiliation(s)
- Wantao Chen
- Department of Oral and Maxillofacial Surgery, School of Stomatology, Shanghai Second Medical University, Shanghai 200011, China
| | | | | | | | | |
Collapse
|
8
|
Moog R, Burger AM, Brandl M, Schüler J, Schubert R, Unger C, Fiebig HH, Massing U. Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. Cancer Chemother Pharmacol 2002; 49:356-66. [PMID: 11976829 DOI: 10.1007/s00280-002-0428-4] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2001] [Accepted: 01/09/2002] [Indexed: 10/27/2022]
Abstract
PURPOSE The in vivo pharmacokinetics (PK), biodistribution and antitumor activity of a new liposomal formulation of gemcitabine (GemLip) were compared to the conventional (clinical) formulation of gemcitabine (GemConv). METHODS Gemcitabine was entrapped in a vesicular phospholipid gel (VPG) consisting of densely packed liposomes. Redispersed VPG containing GemLip consisted of 33% liposomally entrapped and 67% free gemcitabine. The in vivo efficacies of GemLip and GemConv were compared using the subcutaneously growing human soft tissue sarcoma SXF 1301 and the orthotopically growing human bladder cancer BXF 1299T. PK and biodistribution were evaluated using radiolabeled drug and lipid in SXF 1301 tumor-bearing nude mice. RESULTS GemLip was highly active in SXF 1301 at a gemcitabine dose of 6-9 mg/kg (days 1, 8 and 15; dose near the MTD). In the 6-mg/kg groups, complete tumor remissions were observed in seven of eight mice. Equimolar doses of GemConv resulted in only moderate tumor growth inhibition. Even at equitoxic doses (360 mg/kg given on days 1, 8 and 15, or 120 mg/kg on days 1, 5 and 8) GemConv was less active than GemLip. Furthermore, GemLip was active in the orthotopically growing BXF 1299T bladder cancer model at 6 mg/kg and prevented distant organ metastasis. In the PK study, GemLip achieved a 35-fold higher plasma AUC (1680 mg x h/ml) than GemConv (47.6 mg x h/ml). The serum half-lives were 0.15 h for free gemcitabine and 13.3 h for liposomal gemcitabine (6 mg/kg each i.v.). Moreover, gemcitabine levels in tumors were fourfold higher following injection of GemLip than following injection of GemConv. CONCLUSIONS GemLip is a highly effective gemcitabine delivery system which results in superior gemcitabine pharmacodynamics and PK than GemConv. The enhanced in vivo efficacy might be explained by sustained release and passive tumor targeting.
Collapse
Affiliation(s)
- R Moog
- Department of Clinical Research, Tumor Biology Center, Freiburg, Germany
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Obara K, Ghazizadeh M, Shimizu H, Arai R, Tenjin T, Suzuki S, Moriyama Y, Kawanami O. Comparative genomic hybridization study of genetic changes associated with vindesine resistance in esophageal carcinoma. Int J Oncol 2002; 20:255-60. [PMID: 11788885] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023] Open
Abstract
The acquisition of drug-resistance is a major problem for cancer patients undergoing chemotherapy. To clarify genetic alterations in cancer cells that develop drug-resistance, comparative genomic hybridization (CGH) was applied to esophageal squamous cell carcinoma cell lines (SH-1V1, SH-1V2, SH-1V4 and SH-1V8) and chemoresistance-related genes in altered chromosomal regions were evaluated. These cell lines were derived from the parental SH-1 cell line, after multiple steps of selection by an increasing exposure to vindesine. SH-1V8 cells were strongly resistant to vindesine. DNA copy number at 16p which includes the MRP (multidrug resistance related protein) gene was markedly increased in all cell lines examined. Increased DNA copy numbers were found at the regions of 5q31-32, 10q11.1-23, and 14q32-qter in SH-1V8 cells that acquired resistance to other drugs as well. Both SH-1V4 and SH-1V8 showed increased DNA copy numbers at 7q11.1-22, 16q12.1-qter, 19p13.2-13.3, 19q11-13.2 and 20q13.1-qter. The chromosomal region of 7q11.1-22 including MDR-1 (multidrug resistance-1) gene was highly amplified in SH-1V4 and SH-1V8. Amplification of the MRP region suggests the prerequisite of developing resistance to vindesine, and further amplification of MDR-1 may play a critical role in acquiring drug-resistance. Several unknown genes related to the induction of chemoresistance might be concealed in other altered chromosomal regions.
Collapse
Affiliation(s)
- Kunihiko Obara
- Center for Digestive Disease, Nippon Medical School Second Hospital, Kawasaki, Kanagawa 211-8533, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Kawakami Y, Hama S, Hiura M, Nogawa T, Chiba T, Yokoyama T, Takashima S, Tajiri H, Eguchi K, Nagai N, Shigemasa K, Ohama K, Kurisu K, Heike Y. Adenovirus-mediated p16 gene transfer changes the sensitivity to taxanes and Vinca alkaloids of human ovarian cancer cells. Anticancer Res 2001; 21:2537-45. [PMID: 11724319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
BACKGROUND Deletions and point mutations of the p16 gene are detectable in more than 50% of ovarian cancer cells. In this study, we examined the effect of p16 gene transduction on the growth of ovarian cancer cells and on the effect of anti-cancer agents. MATERIALS AND METHODS p16-null human ovarian cancer cell lines, SKOV-3 and OVCAR-5, were used in this study. We transduced the full-length human p16 gene using recombinant adenovirus (AxCA-hp16). RESULTS The spontaneous growth of these cells was significantly inhibited by hp16 transduction. MTT assay revealed that AxCA-hp16 infection induced chemoresistance in both cell lines. Flow cytometric analysis revealed that only hp16 -transduced SKOV-3, were arrested at the G1-phase for 3 days whereas those infected with AxCA-mock and OVCAR-5 infected with both recombinant viruses did not. Western blot analysis showed increased microtubule-associated proteins 4 (MAP4) in both cell lines. CONCLUSION These results suggest that in SKOV-3 cells, G1-arrest induced by p16-transduction prevents paclitaxel- and vindesine-induced cell death, and in OVCAR-5 cells, the other unknown mechanisms play a role of chemoresistance.
Collapse
Affiliation(s)
- Y Kawakami
- Department of Clinical Research, National Shikoku Cancer Center, Matsuyama, Ehime, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Al-Ahmad A, Kümmerer K. Biodegradation of the antineoplastics vindesine, vincristine, and vinblastine and their toxicity against bacteria in the aquatic environment. Cancer Detect Prev 2001; 25:102-7. [PMID: 11270417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
Antineoplastics are excreted into sewage, because patients often poorly metabolize them after administration or they are metabolized into more biologically reactive metabolites. There is little information on their biodegradation and toxicity in aquatic environments. Therefore, the biodegradability of the vinca alkaloids, and their toxicity towards wastewater bacteria were investigated in this study. The biodegradability of vindesine, vincristine, and vinblastine was examined in the closed bottle test (CBT). Additionally, the biodegradability of vinblastine as a model compound of the vinca alkaloids was tested in the Zahn-Wellens test (ZWT). The growth inhibition test with Pseudomonas putida was conducted, and a toxicity control in the CBT and the ZWT was used. The colony-forming units were monitored in the CBT; the test results for the biodegradability after 28 days were: 30% for vincristine, 20% for vindesine, and 10% for vinblastine. Therefore, none of the test compounds met the criteria for being readily biodegradable (> or = 60%). Vinblastine was biodegraded up to 18% in the ZWT after 40 days, and therefore, not inherently. Toxicity towards wastewater bacteria was not found.
Collapse
Affiliation(s)
- A Al-Ahmad
- Institute for Environmental Medicine and Hospital Epidemiology, Freiburg, Germany
| | | |
Collapse
|
12
|
Abstract
BACKGROUND Oncoprotein 18 (op18) was first isolated as a molecule overexpressed in several malignant cells, suggesting a function of op18 in malignant processes, such as differentiation in hematologic malignancies, op18 also was found to enhance microtubule deassembly in the cells. Antimitotic agents that bind to tubulin have been used for chemotherapy to treat solid tumors, such as lung carcinoma. Vinca alkaloids, such as vindesine and vincristine, have commonly been used for chemotherapy of nonsmall cell lung carcinoma. The authors examined the role of op18 in the sensitivity of human lung carcinoma cells to antimitotic agents. METHODS Expression of op18 mRNA was detected in all 17 lung carcinoma cell lines tested by Northern blotting. Oncoprotein 18 cDNA was transfected to SBC-3 human lung carcinoma cells, and the stable transfectants, SBC-3/op1-3, were isolated. The sensitivity of these transfectants against antimitotic agents were examined by the MTT assay in vitro. Cell cycle distribution of the transfectants on DNA histogram was analyzed by flow cytometry. RESULTS Oncoprotein 18-transfected cells showed higher sensitivity to vindesine and vincristine, but not to taxanes. Vindesine-exposure increased the G2/M population of the cell cycle in the Mock transfectants, but not in SBC-3/op1, suggesting that the cell cycle dynamics were altered by op18 expression in SBC-3/op1. CONCLUSION Oncoprotein 18 expression is associated with lung carcinoma cell sensitivity to vindesine and may be able to serve as a surrogate marker for the chemosensitivity to Vinca alkaloids in human lung carcinomas.
Collapse
Affiliation(s)
- K Nishio
- Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan.
| | | | | | | | | | | |
Collapse
|
13
|
Takigawa N, Segawa Y, Ueoka H, Kiura K, Tabata M, Shibayama T, Takata I, Miyamoto H, Eguchi K, Harada M. Combination of nedaplatin and vindesine for treatment of relapsed or refractory non-small-cell lung cancer. Cancer Chemother Pharmacol 2001; 46:272-8. [PMID: 11052624 DOI: 10.1007/s002800000153] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
PURPOSE A phase II study of nedaplatin and vindesine was conducted to evaluate their efficacy and safety for treatment of relapsed or refractory non-small-cell lung cancer (NSCLC). METHODS Between August 1996 and September 1998, 48 patients who had previously received chemotherapy, thoracic radiotherapy, and/or surgery were enrolled in the study. Patients were required to have an Eastern Cooperative Oncology Group performance status of 0 to 2 and an age between 20 and 79 years. Treatment consisted of nedaplatin (80 mg/m2, day 1) and vindesine (3 mg/m2, days 1 and 8) every 3 to 4 weeks. RESULTS Of 48 patients, 7 (14.6%) exhibited an objective response. Four (50%) of eight chemotherapy-naive patients had a partial response. However, of the 40 patients who had received prior chemotherapy, a partial response was observed in only 3 (7.5%). At a median follow-up time of 85.1 weeks, the median survival time was 43.6 weeks (95% confidence interval 34.4-52.7) for patients who had received chemotherapy, with a survival rate of 40% at 1 year. Grade 3 or 4 neutropenia occurred in 43 of 48 patients (90%), and neutropenic fever was observed in 3 of the 43 patients, one of whom died of sepsis. Pharmacokinetic and pharmacodynamic analyses of platinum were performed in 43 patients during the first cycle of chemotherapy. Percent reduction in absolute neutrophil count was correlated not only with the area under the plasma ultrafilterable platinum concentration versus time curve (r = 0.41, P = 0.007) but also with the duration of ultrafilterable platinum concentration above 1 microg/ml (r = 0.41, P = 0.007). Patients with progressive disease exhibited a shorter duration of ultrafilterable platinum concentration over 1 microg/ml (P = 0.046) than those with other responses. CONCLUSION A combination of nedaplatin and vindesine was unsatisfactory as second-line chemotherapy for NSCLC, although the combination was well tolerated. The duration of ultrafilterable platinum concentration above 1 microg/ml was an important pharmacokinetic parameter for predicting both chemotherapy-induced neutropenia and treatment outcome.
Collapse
Affiliation(s)
- N Takigawa
- Department of Internal Medicine, National Shikoku Cancer Center Hospital, Matsuyama, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Yatsunami J, Aoki S, Fukuno Y, Kikuchi Y, Kawashima M, Hayashi SI. Antiangiogenic and antitumor effects of tranilast on mouse lung carcinoma cells. Int J Oncol 2000; 17:1151-6. [PMID: 11078800 DOI: 10.3892/ijo.17.6.1151] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
We examined the effects of tranilast on tumor angiogenesis, tumor growth and metastasis in the mouse Lewis lung carcinoma and C57BL mouse system. Tranilast significantly reduced the dense capillary network induced by Lewis lung cancer cells in a mouse dorsal air sac angiogenesis model. Intraperitoneal administration of tranilast at 200 mg/kg/day reduced the tumor size of mouse Lewis lung carcinoma to about 63% of that of the control and suppressed pulmonary metastasis in a spontaneous system. Immunohistochemistry revealed that tranilast reduced the tumor vascularity and increased apoptosis of the tumor cells in vivo. Tranilast potentiated the inhibition of the tumor growth induced by cyclophosphamide, cis-diamminedichloroplatinum(II), adriamycin and vindesine in vivo. These results suggest that tranilast has antiangiogenic and antitumor effects and might have possible therapeutic applications.
Collapse
Affiliation(s)
- J Yatsunami
- Department of Internal Medicine, Saga Medical School, Saga 849-8501, Japan.
| | | | | | | | | | | |
Collapse
|
15
|
Reinhold U, Ugurel S, Tilgen W, Kadiata MM, Olivares E, Nadi AB, Malaisse WJ. Antitumoral action of 2-deoxy-D-glucose tetraacetate in human melanoma cells. Oncol Rep 2000; 7:1093-7. [PMID: 10948345 DOI: 10.3892/or.7.5.1093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The ester 2-deoxy-D-glucose tetraacetate (2-DOGTA) was recently shown to display cytostatic and cytotoxic activity in various lines of tumoral cells. In the present work, it was found to inhibit cell growth and confer chemosensitivity to cisplatin in two lines of human melanoma cells, poorly responsive to cisplatin. The inhibition of cell growth by 2-DOGTA was apparently not attributable to alteration of either D-glucose utilization or oxidation in these melanoma cell lines. In freshly isolated human melanoma cells, 2-DOGTA also inhibited cell growth, even in cells resistant to standard chemotherapeutic agents, such as temozolomide, cisplatin and/or vindesine. It is proposed, therefore, that 2-DOGTA should be further investigated for the treatment of melanoma patients, whether alone or in combination with known chemotherapeutic agents.
Collapse
Affiliation(s)
- U Reinhold
- Department of Dermatology, The Saarland University Hospital, D-66421 Homburg/Saar, Germany
| | | | | | | | | | | | | |
Collapse
|
16
|
Ogura K, Ohta S, Ohmori T, Takeuchi H, Hirose T, Horichi N, Okuda K, Ike M, Ozawa T, Siba K, Kasahara K, Sasaki Y, Nakajima H, Adachi M. Vinca alkaloids induce granulocyte-macrophage colony stimulating factor in human peripheral blood mononuclear cells. Anticancer Res 2000; 20:2383-8. [PMID: 10953300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
Several anti-cancer drugs are known to have proliferation-related effects on various cells, such as an activation of some transcription factors and an induction of some cytokines. We examined the effect of anti-cancer drugs on granulocyte-macrophage colony stimulating factor (GM-CSF) induction in human peripheral blood mononuclear cells (PBMC). Increase of GM-CSF protein and mRNA were observed in PBMC after exposure to vindesine sulfate (VDS). Induction of GM-CSF protein was dose-dependent and detectable at VDS concentrations of 0.1 microgram/ml. This effect was also observed in response to treatment with other microtuble-depolymerizing agents, vincristine sulfate and vinorelbine ditartrate, but not with cisplatin, etoposide, or paclitaxel. In order to elucidate the mechanism of this phenomenon, we examined the effects of cyclohexamide and actinomycin D on the expression of GM-CSF mRNA. Both of these drugs completely inhibited GM-CSF mRNA expression after VDS exposure, implying that VDS induces de novo GM-CSF synthesis in an indirect manner. As a candidate for the initial signaling, we next examined the role of the IL-1 beta autocrine or paracrine pathways in GM-CSF induction by VDS. IL-1 beta protein and mRNA expression were induced after VDS exposure more rapidly (from 4 hours) than expression of GM-CSF (protein from 12 hours and mRNA from 8 hours). Addition of anti-IL-1 beta antibody partially inhibited induction of GM-CSF by VDS. These results suggest that GM-CSF induction by VDS is partially mediated through the initial generation of IL-1 beta in PBMC.
Collapse
Affiliation(s)
- K Ogura
- First Department of Internal Medicine Showa University, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Nessling M, Kern MA, Schadendorf D, Lichter P. Association of genomic imbalances with resistance to therapeutic drugs in human melanoma cell lines. Cytogenet Cell Genet 2000; 87:286-90. [PMID: 10702697 DOI: 10.1159/000015451] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The reason why human malignant melanomas respond poorly to chemotherapy is not known. In an attempt to identify genes responsible for such resistance or sensitivity to therapeutic drugs, we studied the parental human melanoma cell line MeWo, as well as eight drug-resistant sublines of MeWo. These have low and high levels of resistance to four chemotherapeutic drugs with different modes of action: Vindesine, cisplatin, fotemustine and etoposide. Comparative genomic hybridizations with genomic DNA from these cell lines as probes revealed a number of chromosome gains and losses which occurred upon selective pressure during development of the sublines. The MeWo subline with high resistance to the topoisomerase II inhibitor, etoposide, exhibited the highest number of acquired chromosome imbalances. Interestingly, the two lines with high resistance to cisplatin and fotemustine, respectively, shared three additional imbalances, loss of 9p, loss of distal 12p and gain on distal 15q. The importance of these coincident imbalances is discussed.
Collapse
MESH Headings
- Aneuploidy
- Antineoplastic Agents/pharmacology
- Chromosomes, Human, Pair 12/genetics
- Chromosomes, Human, Pair 15/genetics
- Chromosomes, Human, Pair 9/genetics
- Cisplatin/pharmacology
- DNA Mutational Analysis
- DNA Probes/genetics
- DNA Topoisomerases, Type I/metabolism
- Drug Resistance, Neoplasm/genetics
- Etoposide/pharmacology
- Genome, Human
- Humans
- Melanoma/enzymology
- Melanoma/genetics
- Melanoma/pathology
- Nitrosourea Compounds/pharmacology
- Nucleic Acid Hybridization
- Organophosphorus Compounds/pharmacology
- Selection, Genetic
- Topoisomerase I Inhibitors
- Tumor Cells, Cultured
- Vindesine/pharmacology
Collapse
Affiliation(s)
- M Nessling
- Abteilung Organisation komplexer Genome, Deutsches Krebsforschungszentrum, Heidelberg, Germany
| | | | | | | |
Collapse
|
18
|
Jagetia GC, Adiga SK. Correlation between cell survival and micronuclei formation in V79 cells treated with vindesine before exposure to different doses of gamma-radiation. Mutat Res 2000; 448:57-68. [PMID: 10751623 DOI: 10.1016/s0027-5107(99)00240-7] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Effect of 20 nM vindesine sulphate (VDS) treatment was studied on cell survival, growth kinetics and micronuclei induction in V79 cells exposed to 0-300 cGy of gamma-radiation at 16, 22 and 28 h post-irradiation. Treatment of V79 cells with VDS before exposure to different doses of gamma radiation resulted in a significant decline in cell survival and growth kinetic when compared with the concurrent PBS+irradiation group. The decline in cell survival and growth kinetics was dose related. Similarly, the cell proliferation indices also declined in a dose dependent manner in both PBS+irradiation and VDS+irradiation groups and this decline was higher in VDS+irradiation group in comparison with the PBS+irradiation group. In contrast, the frequency of micronuclei increased in a dose related manner in both PBS+irradiation and VDS+irradiation groups. However, the frequency of micronuclei was significantly greater in the VDS+irradiation group when compared to the PBS+irradiation group at all the post-irradiation time periods studied and the dose response for both groups was linear for all the scoring time periods. The biological response was determined by plotting surviving fraction and micronuclei frequencies on X- and Y-axes, respectively. The plot between surviving fraction and micronuclei induction showed a close correlation. The surviving fraction of V79 cells reduced with the increasing frequency of micronuclei in both groups and the relationship between micronuclei induction and cell survival could be fitted on a linear quadratic model.
Collapse
Affiliation(s)
- G C Jagetia
- Department of Radiobiology, Kasturba Medical College, 3rd Floor, Manipal, Karnataka 576 119, India.
| | | |
Collapse
|
19
|
Beinert T, Binder D, Oehm C, Ziemer S, Priem F, Schweigert M, Stuschke M, Fleischhacker M, Siebert G, Mergenthaler HG, Werner TG, Sezer O, Possinger K. Increased levels of vascular endothelial growth factor in bronchoalveolar lavage of patients with bronchial carcinoma effect of tumour activity and oxidative stress due to radio-chemotherapy? Eur J Med Res 1999; 4:328-34. [PMID: 10471544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023] Open
Abstract
BACKGROUND Vascular endothelial growth factor (VEGF) plays a crucial role in physiological and neoplastic angiogenesis. Moreover, VEGF has been found to be upregulated by conditions associated with the generation of free radicals and reactive oxygen intermediates. In patients with cancer, studies to evaluate VEGF as a measure of tumour activity were carried out. We tested the hypothesis that VEGF is additionally affected by oxidative stress due to anticancer therapy. Moreover, the suitability of epidermal growth factor (EGF) to estimate tumour activity was studied. PATIENTS AND METHODS 60 patients with non-small cell lung cancer (NSCLC) covering different therapy progress and modalities underwent bronchoalveolar lavage. VEGF-, EGF-, albumin- and total protein-concentrations in bronchoalveolar lavage fluid (BALF) and VEGF-levels in blood plasma were studied. RESULTS BALF VEGF-levels were increased in patients with advanced NSCLC before and in anticancer therapy. In patients who had received radiotherapy to the lung prior to chemotherapy, VEGF concentrations were noticeably higher than under sole chemotherapy. Pulmonary endothelial hyperpermeability was found in patients with recently diagnosed tumours and patients undergoing anti-cancer therapy. Evaluation of EGF-levels in BALF revealed no significant influence of tumour activity or cancer therapy on this parameter. CONCLUSION BALF-levels of VEGF are affected by tumour activity and oxidative stress due to anticancer therapy.
Collapse
Affiliation(s)
- T Beinert
- Universitäts-Klinikum Charité, Zentrum für Innere Medizin, Medizinische Klinik und Poliklinik II, Schumannstrasse 20-21, D-10117 Berlin, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Pereira E, Tarasiuk J, Garnier-Suillerot A. Kinetic analysis in living cells of the inhibition of the P-glycoprotein-mediated efflux of anthracyclines by vinca alkaloids. Chem Biol Interact 1998; 114:61-76. [PMID: 9744556 DOI: 10.1016/s0009-2797(98)00036-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Cells that overexpress the mdr 1 gene have decreased steady-state accumulation and increased efflux of many anticancer drugs including anthracyclines and vinca alkaloids. The mechanism(s) of P-glycoprotein-mediated efflux of drugs is (are) still poorly understood. In an attempt to identify mechanism(s) by which multidrug resistance can be circumvented, the cellular accumulation has been examined of pirarubicin, doxorubicin and idarubicin alone and in conjunction with four vinca alkaloid derivatives--vinblastine, navelbine, vindesine and vincristine. The present study was performed using a spectrofluorometric method with which it is possible to follow continuously the uptake and release of fluorescent molecules by living cells, as the incubation of the cells with the drug proceeds. Erythroleukemia K562 cell lines were used. It has been shown that the P-glycoprotein-mediated efflux of these three anthracyclines can be inhibited by vinca alkaloids derivatives. At pH 7.2, 50% of the P-glycoprotein-mediated efflux of daunorubicin and idarubicin was inhibited by about 40 +/- 10 microM vinblastine and that of pirarubicin by 10 +/- 2 microM vinblastine. The vinblastine concentration required to inhibit 50% of the active efflux of these anthracyclines did not depend on the anthracycline concentrations used, indicating that the inhibition was non competitive. The ability of navelbine, vincristine and vindesine to inhibit the active efflux of pirarubicin was also checked; 15 +/- 3 microM navelbine are required to inhibit 50% of the active efflux but at concentrations lower than 100 microM, neither vincristine nor vindesine were able to inhibit this efflux, indicating that the vinca alkaloids compounds which are the most efficient are the most lipophilic. For the four vinca alkaloids, the concentration required to inhibit 50% of the efflux was lower as the pH was higher. A detailed kinetics analysis of the P-glycoprotein-mediated efflux of pirarubicin in the presence of vinblastine indicates a non competitive inhibition with K(I) = 12 +/- 2 microM.
Collapse
Affiliation(s)
- E Pereira
- Laboratoire de Physicochimie Biomoléculaire et Cellulaire (UPRES-A 7033), Université Paris-Nord, Bobigny, France
| | | | | |
Collapse
|
21
|
Abstract
Neurotoxicity forms a major limitation in many clinical applications of vincristine and other powerful vinca alkaloid anticancer drugs. Using the nerve growth factor (NGF) dependent neurite outgrowth from the PC12 pheochromocytoma cell line as an in vitro assay for neurotoxicity, the effect of different concentrations of vincristine (0.55; 1.1 and 11 nM) was compared with that of vindesine and vinblastine. Vincristine in comparatively low concentration (0.55 nM) could significantly decrease the percentage of neurite forming cells from 74% to 32% within a three day incubation period. Especially the longer neurites (> 2 x cell body) proved to be extremely sensitive for vincristine effects. Vinblastine and vindesine were also able to decrease, dose dependently and significantly, the percentage of neurite forming cells. However, the effects observed were less severe than that of vincristine. The sequentially increasing level of neurotoxicity due to vinblastine, vindesine and vincristine, as observed in the neurite outgrowth inhibition correlates well with previous findings from animal models and with data from the clinical practice. Withdrawal of vincristine resulted in a rapid restoration of neurite formation, suggesting the potential reversibility of neurotoxic effects in these cells. These results provide a validation of the PC12 neurite outgrowth assay as a suitable and reliable model for predicting neurotoxicity.
Collapse
Affiliation(s)
- A A Geldof
- Department of Endocrinology/Nucl. Medicine, Academisch Ziekenhuis Vrije Universiteit, Amsterdam, The Netherlands
| | | | | |
Collapse
|
22
|
Jagetia GC, Jyothi P, Krishnamurthy H. Effect of vindesine sulfate on the radiation-induced alterations in mouse spermatogenesis: a flow cytometric evaluation. Mutat Res 1998; 398:163-74. [PMID: 9626976 DOI: 10.1016/s0027-5107(97)00232-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The effect of 0.05 mg/kg body weight of vindesine sulfate was studied on the radiation-induced changes in mouse spermatogenesis at 1, 2, 7, 14, 21, 28, 35 and 70 days post-irradiation. Vindesine administration before exposure to 0, 0.5, 1, 2 and 3 Gy gamma-irradiation resulted in an increase in the radiation-induced perturbations of mouse spermatogenesis at various post-exposure time periods studied. A significant reduction in testicular weight was observed in both DDW + irradiated and VDS + irradiated groups at various post-irradiation time periods, depending on the exposure dose. Vindesine pretreatment resulted in an enhanced killing of spermatogonial cells at day 2 post-exposure at all the exposure doses, except 3 Gy when compared to DDW + irradiated controls. Consequently, the tetraploid (4C) population declined significantly by day 14 post-irradiation followed by a severe depletion in round spermatids (1C) by day 21 post-irradiation. The dose-response relationship for 4C and 1C populations was linear-quadratic at days 14 and 21, respectively. A significant elevation was observed in HC population from days 1 to 21 depending on the exposure dose. The germ cell ratios, viz. 4C:2C, 4C:S-phase, 1C:2C and 1C:4C, showed a significant decline in the VDS + irradiated group when compared to the DDW + irradiated group at various time periods, depending on the exposure dose.
Collapse
Affiliation(s)
- G C Jagetia
- Department of Radiobiology, Kasturba Medical College, Manipal, India
| | | | | |
Collapse
|
23
|
Xu J, Song S, Liu X. [The relationship between in vitro chemosensitivity of human breast cancer to MDR related drugs and expression of mdr-1 gene]. Zhonghua Yi Xue Za Zhi 1997; 77:371-3. [PMID: 9772495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
OBJECTIVE To study the relationship between in vitro chemosensitivity of human breast cancer to MDR related drugs and expression of mdr-1 gene. METHODS We measured the chemosensitivity of 56 human breast cancers to MDR related drugs by MTT assay in vitro and level of mdr-1 mRNA in these samples by RT-PCR technique. RESULTS The expression of mdr-1 gene in the breast cancer resistant to drugs in vitro was increased significantly. The level of mdr-1 mRNA was not correlated with Imax%, but correlated with IC50 statistically. CONCLUSION These results support that the increased expression of mdr-1 gene is a major cause of resistance to MDR related drugs.
Collapse
Affiliation(s)
- J Xu
- North Taiping Road Hospital Cancer Center, Beijing
| | | | | |
Collapse
|
24
|
Arioka H, Nishio K, Heike Y, Abe S, Saijo N. In vitro and in vivo modulation by rhizoxin of non-P-glycoprotein-mediated vindesine resistance. J Cancer Res Clin Oncol 1997; 123:195-200. [PMID: 9177491 DOI: 10.1007/bf01240315] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Rhizoxin is an antineoplastic drug that inhibits tubulin polymerization. In this study, we demonstrated that rhizoxin was approximately twice as active in vitro against a human small-cell lung cancer cell line with non-P-glycoprotein-mediated resistance to vindesine, H69/VDS, as against its parental line, H69. Tubulin polymerization in H69/VDS, demonstrated by Western blot analysis, was inhibited markedly by rhizoxin compared with that in H69, in a concentration-dependent manner. A drug-accumulation study showed that the intracellular rhizoxin level in H69/VDS was 15% lower than that in H69, whereas efflux from H69/VDS was enhanced slightly. These results indicate that enhanced inhibition of tubulin polymerization rather than increased intracellular drug concentration accounted for the higher sensitivity of H69/VDS to rhizoxin. In an experiment using mice with severe combined immunodeficiency and inoculated subcutaneously with H69/VDS, in vivo tumor growth was reduced markedly by three intermittent intraperitoneal doses of rhizoxin compared with that in mice inoculated with H69. Three weeks after the last rhizoxin dose, the relative treated/untreated tumor volumes were 0.29 for H69, but only 0.06 for H69/VDS, indicating that H69/VDS regrowth was minimal even after a 3-week treatment-free period. In conclusion, rhizoxin conquers vindesine resistance of a human small-cell lung cancer cell line in vitro and in vivo.
Collapse
Affiliation(s)
- H Arioka
- Pharmacology Division, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan
| | | | | | | | | |
Collapse
|
25
|
Affiliation(s)
- S Joel
- Medical Oncology Department, St. Bartholomew's Hospital, London, U.K
| |
Collapse
|
26
|
Levêque D, Wihlm J, Jehl F. [Pharmacology of Catharanthus alkaloids]. Bull Cancer 1996; 83:176-86. [PMID: 8695919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Catharanthus alkaloids are antitumoral drugs widely used in the treatment of malignant diseases. This review summarizes different aspects of their pharmacology (mechanism of action, resistance, clinical pharmacokinetics) as well as information on their uses in the clinical setting.
Collapse
Affiliation(s)
- D Levêque
- Laboratoire de pharmacocinétique, Institut de Bactériologie, Strasbourg, France
| | | | | |
Collapse
|
27
|
Nagata S, Masuda K, Nogusa H, Hirano K, Takagishi Y. Absence of lysosomal cleavage in the cytotoxicity mechanism of an immunoconjugate composed of anti-alpha-fetoprotein monoclonal antibody and vindesine analog. Biol Pharm Bull 1996; 19:480-3. [PMID: 8924923 DOI: 10.1248/bpb.19.480] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The effect of lysosomal enzyme inhibition on the cytotoxic activity of an immunoconjugate composed of anti-alpha-fetoprotein monoclonal antibody and vindesine analog (VDS) was studied in vitro using human tumor clonogenic assay (HTCA). Addition of the lysosome enzyme inhibitors, leupeptin and ammonium chloride, to the HTCA system had little influence on the cytotoxicity of this immunoconjugate. In separate experiments, no released VDS was detected by HPLC after incubation with the supernatant of rat liver homogenate without inhibitor. These results show that the immunoconjugate may bypass the lysosomal process and exert its activity as an intact or similar form.
Collapse
Affiliation(s)
- S Nagata
- Shionogi Research Laboratories, Shionogi & Co., Ltd., Osaka, Japan
| | | | | | | | | |
Collapse
|
28
|
Abstract
Vindesine, a cell-cycle-specific agent currently employed in the treatment of some neoplasias, was able to produce a remarkable dose-dependent adrenocortical activation, but it was unable to increase plasma corticosterone in hypophysectomized rats in vivo. In addition, vindesine was able to increase ACTH release in vitro when tested on isolated pituitary cells in culture suggesting a direct involvement of the pituitary gland in the increase of adrenal secretion in vivo.
Collapse
Affiliation(s)
- L Brunetti
- Department of Pharmacology and Pharmacognosy, G. D'Annunzio University, Chieti, Italy
| | | | | | | |
Collapse
|
29
|
Saito T, Hikita M, Kohno K, Tanimura H, Miyahara M, Kobayashi M. Enhanced expression of the multidrug resistance gene in vindesine-resistant human esophageal cancer cells. Oncology 1994; 51:440-5. [PMID: 8052486 DOI: 10.1159/000227380] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
We developed and characterized a new series of low- and high-grade multi-drug-resistant (MDR) cell lines of human esophageal carcinoma. Eight vindesine-resistant clones, SH-1-V1, SH-1-V2, SH-1-V3, SH-1-V4, SH-1-V5, SH-1-V6, SH-1-V7, and SH-1-V8 were isolated from the human esophageal cancer cell line, SH-1, by stepwise selection on exposure to increasing doses of vindesine. SH-1-V1 to SH-1-V8 acquired resistance to vindesine, in a stepwise manner, from 3- to 115-fold over findings in the parental SH-1 cells. The most resistant clone, SH-1-V8, was cross-resistant to other anticancer agents such as vincristine, actinomycin D, and daunomycin, thereby suggesting acquisition of the MDR phenotype. In SH-1-V8 cells, cellular accumulation of vincristine decreased and an MDR reversal agent, cepharanthine, potentiated the cytocidal action of vindesine. The expression of MDR1 mRNA was enhanced and amplification of the MDR1 gene was observed in clones SH-1-V4, SH-1-V5, SH-1-V6, SH-1-V7 and SH-1-V8; expression of MDR1 mRNA was detectable without gene amplification in the remaining 3 clones. The enhanced expression of the MDR1 gene may be involved in the acquisition of vindesine resistance in human esophageal cancer cells.
Collapse
Affiliation(s)
- T Saito
- Department of Surgery I, Oita Medical University, Japan
| | | | | | | | | | | |
Collapse
|
30
|
Nakagawa H, Kobayashi H, Koezuka M, Yamada M, Miyawaki Y, Tokiyoshi K, Kanayama T, Hagiwara Y, Tsuruzono K. [Chemotherapy for metastatic brain tumors with CDDP and other agents: correlation between chemotherapeutic effects and the results of in vitro chemosensitivity tests using collagen gel-embedded culture combined with computerized image analysis in metastatic brain tumors]. No Shinkei Geka 1994; 22:517-23. [PMID: 8015671] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Chemotherapy with CDDP and/or other agents was performed in 15 patients after removal of metastatic brain tumors. A chemosensitivity test using a system of collagen gel-embedded culture and computerized image analysis was performed on the tumors from these patients. The clinical usefulness of the chemosensitivity test was evaluated by comparing chemotherapeutic effects with the results of the test. The rates of correlation of the chemosensitivity test with clinical response on brain MRI was 80%, and that of the chemosensitivity test with clinical response in tumor markers or on primary tumors was 75%. This observation suggests that the chemosensitivity test using collagen gel-embedded culture and computerized image analysis is useful in determining optimal chemotherapy for metastatic brain tumors. In ten multiple metastatic brain tumors, three complete responses, two partial responses, one minor response and four non-responses were observed on MRI. Only one case showed a false negative result on the chemosensitivity test and showed partial response. This result also indicates the effectiveness of chemotherapy based on chemosensitivity testing.
Collapse
Affiliation(s)
- H Nakagawa
- Department of Neurosurgery, Center for Adult Diseases, Osaka
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Abstract
BACKGROUND Clinical response rates in the treatment of patients with disseminated malignant melanoma are low and unpredictable. Several reports have documented that clonogenic assay systems for in vitro drug testing are capable of predicting resistance to therapy in vivo and might provide guidelines to improve clinical response rates. METHODS Specimens from metastatic lesions of patients with malignant melanoma, predominantly from lymph nodes and skin, were disaggregated, exposed to a panel of 10 cytotoxic drugs for 1 hour, and subsequently cultured in agarose. Effects were calculated by the ability to form tumor colonies compared with an untreated control after 7-14 days. A retrospective comparison between the in vitro drug testing result and clinical response was possible in 19 cases. RESULTS An average of 7.3 drugs per specimen were tested. A high degree of resistance was observed against all cytostatic agents studied independently of the tumor site. In 47 of 181 in vitro drug tests, tumor colony formation was reduced by 30-50%; in 17 of 181, the reduction was more than 50%. A retrospective analysis showed no clinical response in 11 cases and one mixed response in which patients received drugs that had been shown to be "resistant" in vitro. CONCLUSIONS These results support the concept that in vitro drug testing promises to help avoid treatment with ineffective drugs and their associated toxic side effects. Furthermore, it may increase the likelihood of obtaining a clinical response in the treatment of disseminated malignant melanoma. The major limitation in the treatment of malignant melanoma is the lack of availability of effective agents for treatment.
Collapse
Affiliation(s)
- D Schadendorf
- University Hospital Rudolf Virchow, Department of Dermatology, Free University, Berlin, Germany
| | | | | | | | | |
Collapse
|
32
|
Zhou-Pan XR, Sérée E, Zhou XJ, Placidi M, Maurel P, Barra Y, Rahmani R. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 1993; 53:5121-6. [PMID: 8221648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Vinblastine biotransformation was investigated by using a human liver microsomes library. The drug was converted into one major metabolite (M) upon incubation with the microsomes. A large interindividual variation in vinblastine metabolism was observed among the samples tested, with a 4.4 ratio between the lowest and the highest metabolic rates. The biotransformation of vinblastine followed Michaelis-Menten kinetics (Km = 6.82 +/- 0.27 microM and Vmax = 0.64 +/- 0.06 nmol/min/mg protein). The involvement of the cytochrome P450 3A subfamily in vinblastine metabolism was demonstrated by the following body of evidence: (a) the competitive inhibition of vinblastine biotransformation by cytochrome P450 3A specific probes with Ki values of 0.17, 22.5, 14.8, and 35.3 microM for ketoconazole, erythromycin, troleandomycin, and vindesine, respectively; (b) the immunoinhibition of vinblastine metabolism by polyclonal anti-cytochrome P450 3A antibodies; (c) the highly significant correlation between the level of cytochrome P450 3A determined by Western blots and vinblastine metabolism (r = 0.759, P < 0.001); (d) the highly significant correlation between erythromycin N-demethylase activity (mediated by cytochrome P450 3A) and vinblastine metabolism (r = 0.83, P < 0.001); (e) the significant correlation between the CYP3A4 mRNA level and vinblastine metabolism (r = 0.60, P < 0.1). Although vincristine and navelbine (members of the Vinca alkaloid family) also inhibit the metabolism of vinblastine, suggesting the involvement of the cytochrome subfamily in their respective metabolisms, other anticancer drugs currently associated with vinblastine in chemotherapy (etoposide, Adriamycin, lomustine, and teniposide) also interfere with vinblastine biotransformation. These metabolic drug interactions may alter the antitumor activity and/or toxicity of the drug during anticancer chemotherapy.
Collapse
Affiliation(s)
- X R Zhou-Pan
- Institut National de la Santé et de la Recherche Médicale, Unité 278, Faculté de pharmacie, Marseille, France
| | | | | | | | | | | | | |
Collapse
|
33
|
Tolis C, Photiou A, Camplejohn RS, Retsas S. Growth inhibitory activity of S12363, a novel vinca alkaloid derivative on human melanoma cell lines. Anticancer Res 1993; 13:161-6. [PMID: 8476208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The growth inhibitory activity of S12363, a new antineoplastic agent which belongs to the vinca alkaloid group incorporating an amino-phosphonate (bioester of valine), was studied on six human melanoma cell lines with different phenotypic characteristics and in vitro growth rates. S12363 was compared with vinblastine (VBL), vincristine (VCR) and vindesine (VDS) using the MTT assay. Inhibition was time- and dose-dependent. Overall, IC50 values ranged from 24-6770nM and 4.6-11.6 nM for the reference drugs and for S12363 respectively, after exposure for 1 hr. All the vinca alkaloids were more active when cells were exposed continuously for 72 hrs, inhibition by S12363 was greater than the reference drugs (p < 0.05 in 15/18 comparisons). The activities of VDS and S12363 were also compared using the clonogenic assay. IC50 values ranged from 45-500 nM and 17-75 nM respectively. On a molar basis, S12363 was significantly more active than VDS (ANOVA p < 0.0001). The shape of the cell survival curve obtained with S12363 was exponential, whereas that of VDS was of the exponential-plateau type. Furthermore, survival with higher concentrations of S12363 was inversely related to cells seeded. Cell cycle analysis showed these compounds to block cells in G2+M after exposure to their respective IC50 concentrations for 1 hr. This effect was obtained using a lower S12363 concentration. In summary, S12363 proved to be 18-83 times more active than the reference drugs in the MTT and 3-11 times more active than VDS in the clonogenic assay. Its high potency and dissimilar cell survival profile indicate that this compound possesses different biological properties, and therefore merits further in vivo evaluation.
Collapse
Affiliation(s)
- C Tolis
- Catherine Griffiths Cancer Research Laboratory, Medical Oncology Unit, Westminster Hospital, London, U.K
| | | | | | | |
Collapse
|
34
|
Abstract
Mechanisms responsible for drug resistance in human esophageal cancer cell lines were investigated. Three cell lines established from human esophageal carcinoma (TE-1, SH-1, and TH) showed different sensitivities to vindesine, vincristine, cisplatin (CDDP), etoposide (VP-16), and pepleomycin. Both SH-1 and TH cell lines were twofold to sevenfold more resistant to pepleomycin, vindesine, and vincristine than TE-1 was. SH-1 showed twofold more resistance to CDDP than either TE-1 or TH did, and TH and TE-1 showed a 3-fold or 1.5-fold more resistance, respectively, to VP-16 than SH-1 did. The accumulation of tritiated vincristine in SH-1 and TH was approximately 50% that in TE-1. Two multidrug resistance reversal agents, cepharanthine and a synthetic dihydropyridine analogue (NK-252; Nikken Chemicals, Saitama, Japan), potentiated the cytocidal actions of vindesine against SH-1, TH, and TE-1 cells, with no apparent expression of P-glycoprotein in the three cell lines. The glutathione S-transferase pi gene was expressed in all three cell lines. DNA topoisomerase II levels were lowest in TE-1, followed by SH-1 and TH, although the accumulation of tritiated VP-16 was less in both TH and SH-1 than in TE-1. Differential sensitivities to anti-cancer drugs appear to be mediated through pleiotropic mechanisms.
Collapse
MESH Headings
- ATP Binding Cassette Transporter, Subfamily B, Member 1
- Antineoplastic Agents/pharmacology
- Blotting, Northern
- Blotting, Western
- Carcinoma, Squamous Cell/chemistry
- Carcinoma, Squamous Cell/drug therapy
- Carcinoma, Squamous Cell/genetics
- DNA Topoisomerases, Type II/analysis
- Drug Resistance/physiology
- Esophageal Neoplasms/chemistry
- Esophageal Neoplasms/drug therapy
- Esophageal Neoplasms/genetics
- Etoposide/pharmacology
- Gene Expression
- Glutathione Transferase/genetics
- Humans
- Membrane Glycoproteins/analysis
- RNA, Neoplasm/isolation & purification
- Tumor Cells, Cultured/drug effects
- Tumor Stem Cell Assay
- Vincristine/pharmacology
- Vindesine/pharmacology
Collapse
Affiliation(s)
- T Saito
- Department of Surgery I, Oita Medical University, Japan
| | | | | | | | | | | |
Collapse
|
35
|
Kubota R, Kubota K, Yamada S. [Enhancement of the effects of anticancer agents on B16 melanoma cells by combination with cepharanthine--I. Alkaloids]. Gan To Kagaku Ryoho 1992; 19:2163-7. [PMID: 1444481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The anticancer effect of a podophyllotoxin derivative, etoposide (ETOP), and the vinca alkaloids, vincristine (VCR) and vindesine (VDS), on the colony forming efficiency (CFE) of B16 melanoma cells, and the CFE inhibition by the combination with a biscoclaurine alkaloid, Cepharanthine (Ceph) were studied in vitro. By combination with Ceph, CFE was reduced about 44% for ETOP, 31% for VCR and 30% for VDS compared to CFE without Ceph. Therefore, the effect of each anticancer agent was enhanced by combination with Ceph, especially that of Ceph and ETOP. The combination effect was greater when the low concentration of the agents was used. From the present study, the combination of ETOP and Ceph appears to be the more effective form of treatment.
Collapse
Affiliation(s)
- R Kubota
- Dept. of Radiology & Nuclear Medicine, Tohoku University, Sendai, Japan
| | | | | |
Collapse
|
36
|
Photiou A, Sheikh MN, Bafaloukos D, Retsas S. Antiproliferative activity of vinorelbine (Navelbine) against six human melanoma cell lines. J Cancer Res Clin Oncol 1992; 118:249-54. [PMID: 1577845 DOI: 10.1007/bf01208613] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
We compared in vitro the cytotoxic activity of vinorelbine (VRB) (Navelbine, 5'-nor-anhydro-vinblastine) a novel Vinca alkaloid, with that of vinblastine (VBL) vincristine (VCR) and vindesine (VDS). Five continuous human melanoma cell lines (C32, G361, StMl11a, StMl12d and StMl14a) and a new line WHMel 1, were used in this study. In growth-inhibition assays, VDS and VRB exhibited comparable cytotoxicity against the C32 and G361 melanoma lines; the effect being dose- and time-dependent. VRB appeared less inhibitory compared to VDS in the lowest concentrations (0.1-1 nM). The same activity was observed with 0.1-1 microM. These drugs exhibited comparable growth inhibition at clinically achievable doses. The MTT assay was used to compare VBL, VCR, VDS, and VRB. Overall IC50 values (concentration required to reduce viability by 50%) ranged from 1 pM to 10 nM. The reduction in cell viability with VRB was similar to that observed with the reference drugs in four out of five lines tested by this method. However a trend was observed for IC50 values to be lower with VBL and VDS. In clonogenic assays (StMl11a, StMl12d and StMl14a lines, 1 h exposure) VRB and VDS produced the same reduction in survival. Survival curves were exponential followed by a terminal plateau. IC50 values ranged from 60 nM to 70 nM. Our results indicate that VRB has in vitro activity against six melanoma lines with differing phenotypic characteristics.
Collapse
Affiliation(s)
- A Photiou
- Catherine Griffiths Cancer Research Laboratory, Westminster Hospital, London, UK
| | | | | | | |
Collapse
|
37
|
Abstract
The effect of vindesine (VDS) on methotrexate (MTX) disposition was studied in bile-drained rats administered VDS prior to [3H]MTX, and in isolated rat hepatocytes and rat liver homogenate concomitantly incubated with MTX and VDS at 37 degrees. In vivo, 7-hydroxylation was reduced by 0.65 mg/kg VDS. In VDS-treated animals, biliary recovery of the MTX dose (50 mg/kg) as 7-hydroxymethotrexate (7-OH-MTX) (1.75 +/- 0.2%, mean +/- SEM) was significantly reduced compared to controls (2.83 +/- 0.57%). In vitro, hydroxylation of MTX (10-200 microM) in hepatocytes was reduced by 14.3 and 66.4% (means) at 12.5 and 100 microM VDS, respectively. With increasing VDS concentrations up to 100 microM, a reduction in intracellular MTX accumulation could account for the decreased MTX hydroxylation. Experiments in a cell free system gave no evidence of inhibition of 7-OH-MTX formation by VDS. In vitro MTX transport studies demonstrated that VDS inhibited the hepatocellular influx of MTX, as (1) the accumulation of MTX corresponded inversely to increasing VDS concentrations and (2) the MTX efflux was not increased by VDS. The apparent Ki for VDS inhibition of MTX influx was 57 microM. We suggest that VDS, by reducing the 7-OH-MTX formation in liver cells, may have implications for combination chemotherapy regimens which include MTX.
Collapse
Affiliation(s)
- R M Bremnes
- Department of Pharmacology, University of Tromsø, Norway
| | | | | | | | | |
Collapse
|
38
|
Lindén CJ. Chemosensitivity spectrum of a human pleural mesothelioma xenograft grown in athymic rats. In Vivo 1991; 5:375-80. [PMID: 1810423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
A human pleural mesothelioma tumour line (AKG) serially transplantable as a subcutaneously growing xenograft in athymic rats was evaluated for chemosensitivity to six antitumour drugs. Drug effects were assessed as the reduction of the area under the tumour volume curve (1-AUC) and as specific growth delay (SGD), resulting from the maximum tolerable dose (MTD) intraperitoneally in athymic rats. SGD greater than 2 or (1-AUC) greater than 0.85 were used as criteria of an active drug at the MTD. Etoposide (40 mg/kg), vincristine (0.9 mg/kg) and vindesine (0.8 mg/kg) were found to be inactive. Cisplatin (CDDP; 8 mg/kg) and carmustine (BCNU; 40 mg/kg) were found to be active resulting in (1-AUC)s of 1.04 and 0.88, respectively. Although mitomycin C (MC) at the MTD of 1.8 mg/kg resulted in a (1-AUC) of only 0.81, the SGD at a dose of 1.5 mg/kg was greater than 2 and therefore the drug was regarded as active. Furthermore, a combination of CDDP 3 mg/kg and MC 1.25 mg/kg was found to be active resulting in (1-AUC) = 0.90 and SGD = 4.70. The combination of CDDP and MC seems to be a promising regime warranting further studies.
Collapse
Affiliation(s)
- C J Lindén
- Department of Lung Medicine, University Hospital, Lund, Sweden
| |
Collapse
|
39
|
Zouboulis CC, Garbe C, Krasagakis K, Krüger S, Orfanos CE. A fluorometric rapid microassay to identify anti-proliferative compounds for human melanoma cells in vitro. Melanoma Res 1991; 1:91-5. [PMID: 1726673 DOI: 10.1097/00008390-199106000-00003] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
A simple, rapid and reproducible assay for the determination of melanoma cell proliferation in vitro is described, based on the hydrolysis of a fluorogenic substrate by cell esterases in the cytoplasm of living cells. Human melanoma cells were cultured at several densities in 96-well culture plates for 24 h and were then incubated with 4-methylumbelliferyl heptanoate. The generated fluorescence showed a strong correlation with the cell numbers, similar to those assessed by determining the [3H]thymidine incorporation into cellular DNA and by quantifying the fluorescence obtained after DNA labelling with Hoechst 33258. The latter, however, was less sensitive and exhibited higher standard deviations. In addition, the method reliably detected the anti-proliferative effects of the anti-cancer compounds cisplatin and vindesine. It is, therefore, suggested that the fluorometric assay with 4-methylumbelliferyl heptanoate as substrate could prove useful for the screening of potential anti-cancer agents with anti-proliferative activity.
Collapse
Affiliation(s)
- C C Zouboulis
- Department of Dermatology, Free University of Berlin, Germany
| | | | | | | | | |
Collapse
|
40
|
Abstract
The effect of one of the vinca alkaloids derivatives, vindesine (VDS), on the ultrastructure of normal peripheral blood cells and leukemic lymphoblasts was examined in vitro. The drug caused an increase in the size of polymorphonuclear specific granules, but exerted no effect on the internal ultrastructure of control lymphocytes platelets, or leukemic lymphoblasts. However, the surface ultrastructure of all cell types examined showed alterations which were dose-dependent. The question whether the lack of internal impairment in the presence of membral alterations may be due to the relatively short exposure time to the drug is discussed.
Collapse
Affiliation(s)
- M Djaldetti
- Department of Medicine B, Hasharon Hospital, Golda Medical Center, Petah-Tiqva, Israel
| |
Collapse
|
41
|
Van Belle SJ, De Smet MC, De Mey JE, Storme GA. Cellular pharmacokinetics of vinblastine and other vinca alkaloids in MO4 cells. Anticancer Res 1991; 11:465-71. [PMID: 2018383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Accumulation of vinblastine has been studied in different types of cancer cells. We measured the intracellular concentration of vinblastine in MO4 cells and compared it to its extracellular concentration in culture medium. We observed that the ratio of accumulation, expressed as the ratio of intracellular over extracellular vinblastine, was dose-dependent. An initial accumulation level was reached within 30 min and a second dose-induced level after 48 hours. This remained constant for another 5 days. Intracellular accumulation was also seen for vincristine and vindesine but here the phenomenon was less dose-dependent and the maximum level was reached after 6 hours. The accumulation ratio of a single vinca alkaloid in MO4 cells is not different from combined simultaneous exposure with 2 or 3 of the drugs. Energy blocking by sodium azide resulted in an inhibition of the supplementary but not the initial level of vinblastine accumulation. After washing out the medium for vinblastine the intracellular concentration remained about 60 micrograms/ml for 1 microgram/ml vinblastine added to the medium. Based on these results, it is concluded that the accumulation of vinblastine is only partially based on an energy mediated mechanism, in which binding of the drug to at least two types of sites may play an important role.
Collapse
Affiliation(s)
- S J Van Belle
- Oncology Center Vrije Universiteit Brussel, Cancer Research Unit, Belgium
| | | | | | | |
Collapse
|
42
|
Abstract
Antitumor activities of IKP-104, a 4(1H)-pyrizinone derivative, were investigated with cultured tumor cell lines and implanted tumors in mice. IKP-104 inhibited the growth of cultured murine tumor cell lines (L1210 leukemia, Lewis lung carcinoma and B16 melanoma) and human tumor cell lines (K562 leukemia and HeLa cervical carcinoma). It also had antitumor effects on implanted murine ascitic tumors (L1210 leukemia and sarcoma 180) and a murine solid tumor (Lewis lung carcinoma). IKP-104 could be classified as a phase-dependent cytostatic drug based on the mode of growth inhibition of cultured B16 melanoma cells compared with those of several other antitumor agents. The effect of IKP-104 on the cell cycle traverse of cultured B16 melanoma cells was estimated by morphological and flow cytometric analyses. Cells accumulated in the mitotic phase, and abortive mitosis or polyploidy or multinucleation was induced from 6 h after exposure to IKP-104. Based on these results, IKP-104 is expected to be useful for the treatment of tumors, and its mode of action seemed to be similar to that of metaphase arrestants such as colchicine or vinca alkaloids.
Collapse
Affiliation(s)
- F Mizuhashi
- Life Science Research Institute, Kumiai Chemical Industry Co. Ltd., Shizuoka
| | | | | | | | | | | |
Collapse
|
43
|
Leonce S, Anstett M, Combe-Perez V, Pierre A. Flow cytometric evaluation of the cell cycle perturbations induced by S12363, a new vinca alkaloid derivative. Anticancer Drugs 1990; 1:179-83. [PMID: 2131051 DOI: 10.1097/00001813-199012000-00010] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
L1210 cells treated for 21 hours with S12363, a new vinca alkaloid derivative and the parent compounds (vinblastine, vincristine, vindesine) at equitoxic concentrations were found, by flow cytometry, to be equally accumulated in the G2 + M phase of the cell cycle. The chromatin structure of these cells was then analyzed in order to quantify with high precision the percentage of cells in mitosis. S12363 was found to accumulate, from the first hours of treatment (4-8 hours), and at lower concentrations, a higher percentage of cells in the M phase than the reference drugs. Taking into account previously published studies concerning the characteristics of vinblastine and vincristine uptake, our results are compatible with a facilitated uptake of S12363.
Collapse
Affiliation(s)
- S Leonce
- Institut de Recherches Servier, Suresnes, France
| | | | | | | |
Collapse
|
44
|
Abstract
The effects of the combination of cisplatin and other cytotoxic agents were studied in vitro. When A549 lung cancer cells were treated simultaneously with cisplatin and other cytotoxic agents, cisplatin additively increased the cytotoxic effects of etoposide, mitomycin C, adriamycin, 5-fluorouracil and 1-beta-D-arabinofuranosylcytosine, but antagonised those of vincristine, vindesine, vinblastine and podophyllotoxin. The antagonism between cisplatin and vincristine was also observed with HT29 colon cancer cells. NC65 renal carcinoma cells and A431 epidermoid carcinoma cells when these cells were simultaneously exposed to both agents. When A549 cells were exposed to cisplatin and vincristine sequentially, the antagonism between them was evident when cells were pretreated with cisplatin but not when treated in the opposite sequence. Therefore, when combination chemotherapy including cisplatin and vinca alkaloids is given, possible antagonism between them should be considered, especially in determining the schedule of drug administration.
Collapse
Affiliation(s)
- K Lee
- First Department of Medicine, Kyoto University, Japan
| | | | | | | | | | | | | |
Collapse
|
45
|
Fujikane T, Shimizu T. [Studies on cell cycle analysis using a monoclonal antibody to bromodeoxyuridine (BrdU labeling method)]. Nihon Gan Chiryo Gakkai Shi 1988; 23:1538-50. [PMID: 3183461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
46
|
Dodion P, Sanders C, Georges P, Kenis Y. In vitro chemosensitivity of brain tumors to cisplatin and its analogues, iproplatin and carboplatin. Cancer Chemother Pharmacol 1988; 22:80-2. [PMID: 3293841 DOI: 10.1007/bf00254187] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
The human tumor stem-cell assay was used to investigate the in vitro chemosensitivity of 27 evaluable samples to cisplatin and its analogues, iproplatin and carboplatin, as well as to BCNU, teniposide, vindesine, and dibromodulcitol. All agents exhibited some antitumor activity with the exception of dibromodulcitol (zero response out of 19 evaluable samples). Vindesine, BCNU, and carboplatin were the three most active compounds, with response rates of 29%, 23%, and 22%, respectively. There was a lack of complete cross-resistance between carboplatin and cisplatin as well as between carboplatin and BCNU. Our data suggest that clinical studies with carboplatin and combinations of vindesine plus cisplatin and its analogues may be worthwhile.
Collapse
Affiliation(s)
- P Dodion
- Laboratoire d'Investigation Clinique H. J. Tagnon, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | | | | | | |
Collapse
|
47
|
Rivera-Fillat MP, Pallarés-Trujillo J, Domènech C, Grau-Oliete MR. Comparative uptake, retention and action of vincristine, vinblastine and vindesine on murine leukaemic lymphoblasts sensitive and resistant to vincristine. Br J Pharmacol 1988; 93:902-8. [PMID: 3390658 PMCID: PMC1853905 DOI: 10.1111/j.1476-5381.1988.tb11478.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
1. The uptake and retention of vincristine (VCR), vinblastine (VBL) and vindesine (VDS) were evaluated comparatively with respect to their cytotoxic action on a murine lymphoblastic leukaemia (L5178Y). 2. The same parameters were measured on a derived subline of cells resistant to VCR (L5178Y/r) in order to determine whether the different degree of resistance to each alkaloid correlates with the amount of drug associated with the cells. 3. VCR was the most active on L5178Y cells (IC50 = 5.8 x 10(-9) M) while the activity of VBL and that of VDS were similar (IC50 4.4 x 10(-8) M and 3.5 x 10(-8) M, respectively). Nevertheless, a considerably larger amount of VBL was taken up by the cells compared to VDS, although there were no significant differences in their cytotoxic action. 4. The VCR resistant cell line also expressed resistance to VDS, whose IC50 was increased by a factor of 11.4, but not to VBL. However, the uptake and retention of the three alkaloids were similarly reduced in L5178Y/r cells regardless of the degree of resistance expressed. 5. Although a decreased drug uptake and/or retention by the cells provides an explanation for the resistance to vinca alkaloids, they do not seem to be the only factors accounting for the resistance shown by the cell line which we have isolated. 6. The results seem to indicate that part of the VBL taken up by the cells is not used to induce the cytotoxic effect, but is diverted to some cellular compartment(s) or rate controlling process(es) which are different from the target that mediates its cytotoxic action.
Collapse
Affiliation(s)
- M P Rivera-Fillat
- Departamento de Farmacología y Patología Experimental, CSIC, Barcelona, Spain
| | | | | | | |
Collapse
|
48
|
Walther H, Müller H, Aigner KR. Inhibition of proteases during extracorporeal extremity perfusion experimental and clinical results. Adv Exp Med Biol 1988; 240:565-7. [PMID: 2469310 DOI: 10.1007/978-1-4613-1057-0_73] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
In an experimental and clinical study a significant reduction of the postoperative edema after extracorporeal extremity perfusion under addition of Aprotinin was observed. Together with reduction of edema usually expected complications like pain and peripheral nerve damage could be reduced significantly. Preliminary, yet unpublished data on cytostatic infusion of the pancreas also indicate that intraarterial Aprotinin when given simultaneously may prevent pancreatitis. It is mandatory Aprotinin to be given early enough in sufficiently high dose and there seems to be an advantage when the arterial route is used.
Collapse
Affiliation(s)
- H Walther
- Department of General and Oncologic Surgery, Trosberg Hospital
| | | | | |
Collapse
|
49
|
Safa AR, Glover CJ, Felsted RL. Identification of Vinca alkaloid acceptors in P388 murine leukemia cells with a photoactive analogue of vinblastine. Cancer Res 1987; 47:5149-54. [PMID: 3621200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The cytotoxic, antimitotic, and growth inhibition properties of a photoactive analogue of vinblastine, N-(p-azidobenzoyl)-N'-beta-aminoethylvindesine (NABV), and vinblastine on P388 murine leukemia cells were compared. After 72-h exposure, the 50% drug-inhibitory concentrations for exponentially growing P388 leukemic cells were 1.2 nM for NABV and 0.6 nM for vinblastine. The ultrastructural effects of NABV and vinblastine on P388 cells were similar: formation of tubulin paracrystals; mitotic arrest (C-mitosis); increased post-C-mitotic multinucleated cells; increased number of annulate lamellae; and the appearance of intracytoplasmic paired cisternae. [3H]NABV was used to identify Vinca alkaloid binding sites in P388 cells by photoaffinity labeling. After irradiation at 302 nm, radioactive Vinca alkaloid binding components were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and identified in 1-mm gel slices. The most prominent photolabeled species were Mr 44,000, 54,000, and 75,000 polypeptides located in the 100,000 X g supernatant fraction. The Mr 54,000 component was also observed in the membrane fraction. Specific photolabeling of Mr 54,000 and 44,000 polypeptides was blocked in the presence of 20 microM excess of vinblastine and was saturable with half-maximal saturation concentrations of 0.18 and 0.4 microM [3H]NABV, respectively. The Mr 54,000 component was identified as a tubulin subunit by immunoprecipitation with antitubulin monoclonal antibodies. Since NABV and vinblastine have similar pharmacological and biological properties, this photoactive analogue may be useful for identifying important Vinca alkaloid cellular acceptors which may be responsible for drug cytotoxic and antineoplastic activities.
Collapse
|
50
|
Fukui H, Ide H, Hanyu F, Ikemoto H, Okushima N, Murata Y, Sato Y, Yamada A. [A 6-day subrenal capsule assay for predictive testing of primary esophageal cancers]. Gan To Kagaku Ryoho 1987; 14:1106-10. [PMID: 2436579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Subrenal Capsule Assay (SRCA) as a chemosensitivity test was performed on 14 esophageal squamous cell carcinomas in order to select a more effective form of chemotherapy. Of the 14 assays, 12 were evaluable. Mice were treated with anticancer agents (e.g. Cisplatin, Bleomycin, Methotrexate, Vindesine) on days 1 and 3 after transplantation, and on day 6, the sensitivities were determined. Fresh esophageal cancers yielded an evaluable assay rate of 74%. The implant grew progressively for six days in the remaining group of control mice. Histologically, host cell infiltration at the border of the implant was observed from day 3 after transplantation, and cells had degenerated or had been partially replaced by scar tissue by day 6. The results of chemosensitivity tests differed according to the anticancer agent used or from case to case. Clinically, correspondence between the assay results and clinical results was obtained in 5 out of 7 cases. SRCA is a new promising chemosensitivity test which is clinically useful, and the present results indicated the feasibility of its use in developing an effective chemotherapy for esophageal cancer.
Collapse
|